Investigative radiology · 2009
Ultra-low-dose, time-resolved contrast-enhanced magnetic resonance angiography of the carotid arteries at 3.0 tesla.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lohan Derek G, Tomasian Anderanik, Saleh Roya S, Singhal Aparna, Krishnam Mayil S, Finn J Paul
Аннотация
PURPOSE: To determine whether time-resolved magnetic resonance angiography (TR-MRA) with ultra-low-dose gadolinium chelate (1.5-3.0 mL) can reliably detect or rule out hemodynamically significant disease in the carotid-vertebral artery territory.
MATERIALS AND METHODS: Hundred consecutive patients (62 women, 38 men, mean age = 56.6 years) underwent both TR-MRA and standard high-resolution contrast-enhanced magnetic resonance angiography (CE-MRA), having been randomized to 1 of 2 groups; group A receiving a contrast dose of 1.5 mL for TR-MRA and group B receiving 3.0 mL. For scoring purposes the arterial system was divided into 21 segments. All TR-MRA and CE-MRA studies were blindly assessed by 2 radiologists for overall image quality, segmental arterial visualization, grading of arterial stenosis/occlusion, and incidence and severity of artifact. TR-MRA findings were directly compared with those of the corresponding CE-MRA examinations.
RESULTS: Group A TR-MRA studies were of significantly inferior overall image quality compared with those of the corresponding CE-MRA examinations (P = 0.01 for both observers). In group B, overall image quality was similar for TR-MRA and single-phase CE-MRA examinations. On a segmental basis, a higher number of "insufficient quality" segments were identified in group A TR-MRA studies than in group B. A similar reduction in the incidence of artifacts was observed for group B relative to group A TR-MRA studies. Both groups A and B TR-MRA studies were of high specificity, negative predictive values, and accuracy (>97%).
CONCLUSION: Ultra-low dose TR-MRA may be performed with 3 mL of gadolinium chelate with preservation of overall image quality and arterial segmental visualization relative to single phase CE-MRA, whereas a 1.5 mL contrast dose is associated with more suboptimal studies. Nonetheless, even at doses as low as 1.5 mL, TR-MRA can exclude arterial stenosis or occlusion.
MATERIALS AND METHODS: Hundred consecutive patients (62 women, 38 men, mean age = 56.6 years) underwent both TR-MRA and standard high-resolution contrast-enhanced magnetic resonance angiography (CE-MRA), having been randomized to 1 of 2 groups; group A receiving a contrast dose of 1.5 mL for TR-MRA and group B receiving 3.0 mL. For scoring purposes the arterial system was divided into 21 segments. All TR-MRA and CE-MRA studies were blindly assessed by 2 radiologists for overall image quality, segmental arterial visualization, grading of arterial stenosis/occlusion, and incidence and severity of artifact. TR-MRA findings were directly compared with those of the corresponding CE-MRA examinations.
RESULTS: Group A TR-MRA studies were of significantly inferior overall image quality compared with those of the corresponding CE-MRA examinations (P = 0.01 for both observers). In group B, overall image quality was similar for TR-MRA and single-phase CE-MRA examinations. On a segmental basis, a higher number of "insufficient quality" segments were identified in group A TR-MRA studies than in group B. A similar reduction in the incidence of artifacts was observed for group B relative to group A TR-MRA studies. Both groups A and B TR-MRA studies were of high specificity, negative predictive values, and accuracy (>97%).
CONCLUSION: Ultra-low dose TR-MRA may be performed with 3 mL of gadolinium chelate with preservation of overall image quality and arterial segmental visualization relative to single phase CE-MRA, whereas a 1.5 mL contrast dose is associated with more suboptimal studies. Nonetheless, even at doses as low as 1.5 mL, TR-MRA can exclude arterial stenosis or occlusion.